Clinical Opinion – Poll of the week Poll of week 5 7Created on December 04, 2021Poll of the Week 5Which of the following is true for role of Letermovir in management of CMV Reactivation and Infection in Allogeneic Blood and Marrow Transplant Recipients? Letermovir is approved for prophylaxis CMV disease in adult CMV-seropositive recipients The recommended dose of Letermovir is 480 mg once daily PO/IV If letermovir is co-administered with ciclosporin, the dosage of letermovir should be halved All of these are true regarding role of Letermovir in management of CMV Reactivation and Infection Letermovir is approved for prophylaxis CMV disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). The recommended dose is 480 mg once daily BUT, if letermovir is co-administered with ciclosporin, the dosage of letermovir should be decreased to 240 mg once daily. Letermovir should normally be started on the day of transplant (Day 0) (but it may be started any day up to 28 days post-transplant). Letermovir may be started before or after engraftment. Prophylaxis with Letermovir is normally stopped at day +100 post-transplant (unless stopped earlier in case of CMV reactivation requiring initiation of pre-emptive therapy). Change/Click on page numbers below for next Question Pages: 1 2 3 4 5
